ing of the lesions would have been more rapid in the drugtreated group.
Introduction
Biochemical findings suggesting osteomalacia are quite often seen in epileptic patients treated with major anticonvulsant drugs (Wright, 1965; Schmid, 1967; Kruse, 1968; Dent et Richens and Rowe, 1970; Hunter et al., 1971) . The suggestion was made that induction of liver enzymes concerned with hydroxylation of vitamin D might be responsible for this disturbance of calcium metabolism . Several findings have supported this hypothesis. The urinary excretion of glucaric acid, which is an index of liver-enzyme induction, correlates inversely with the serum calcium levels in epileptics (Hunter et al., 1971) . Other investigations have shown low serum levels of 25-hydroxycholecalciferol (Hahn et al., 1972; Stamp et al., 1972) , the main circulating metabolite of vitamin D, (Ponchon and DeLuca, 1969) . With regard to the clinical significance of these drug-induced phenomena, a number of authors have reported radiological signs of rickets (Kruse, 1968; Berger and Munde, 1970; Lussier-Lazaroff and Fletcher, 1971; Lassker et al., 1971; Stogmann, 1971) . However, the published reports disagree considerably as to the incidence of anticonvulsant rickets in epileptic children. This may be due to the inborn qualitative nature of the radiological examination. Bone biopsy has been done in only a few patients (Dent et al., 1970) , and this method is similarly difficult to quantitate. It is possible to express the bone mineral content quantitatively by means of photon absorptiometry, and this has been used to show a low bone mineral content in small groups of epileptic patients (Linde et al., 1971; Christiansen et al., 1972 .
Though most epileptics are outpatients the major reports on anticonvulsant osteomalacia have concerned inpatients Hunter et al., 1971; Stamp et al., 1972) . Naturally, the question arises whether the large number of patients on anticonvulsant therapy should be treated with vitamin D, and if this is so what dose of vitamin D should the patient receive ? A subsidiary question might be: which patients should have vitamin D, and how should they be selected?
Before these questions can be answered it is necessary to decide on a method of quantitating bone demineralization in anticonvulsant osteomalacia, and to apply it to a large, representative sample of epileptic outpatients before and after treatment with therapeutic doses of vitamin D. To minimize unwanted influences the therapeutic trial should be carried out in a controlled way over a reasonably short time-preferably during the winter.
We report here a controlled therapeutic trial in epileptic outpatients, where photon absorptiometry was used to evaluate bone mineral content (B.M.C.). Furthermore, the serum levels of calcium and alkaline phosphatase were determined in order to compare the biochemical and the bone indices of osteomalacia.
Epileptic Patients and Control Subjects EPILEPTIC PATIENTS
A total of 249 epileptics who attended the epilepsy clinic at Glostrup Hospital at regular intervals were invited to take part in the investigation. All fulfilled the following criteria: they were outpatients receiving treatment with one or two major anticonvulsant drugs (phenytoin, phenobarbitone, and primidone); aged between 21 and 70 years; there were no symptoms of digestive or renal diseases; all had a normal serum creatinine value; most were fully capable of doing their daily work, and none were disabled. Of these 249 patients 23 declined the invitation. This left 226 who agreed to participate after the nature of the trial was explained to them. The sex and age of the patients, the dose of anticonvulsant drugs, serum levels of anticonvulsants, and duration of treatment are shown in This group servcd as a reference group of serum calcium and serum alkaline phosphatase levels. Group 3 (20 subjects, all members of the laboratory staff).-Ten women and 10 men aged 21 to 33 years (mean 28 years) agreed to participate in the controlled therapeutic trial (see under Procedure). Preliminary results from this group have previously been published .
The bone mineral content was determined by direct photon absorptiometry on both forearms ( fig. 1 ). Antebrachium is fixed in a Plexiglass container filled with distilled water. The source of radiation (25 mCi 125I) and the detector are fixed in a holder (Mazess, 1971; Christiansen and Rddbro, 1973 and C and group 3 of normal subjects were allocated to a "vita-min D treatment group" or a "placebo treatment group," using random sampling numbers (Bradford Hill, 1967 (Hansen, 1973) .
In connexion with the final examination (at time t,) the epileptic patients answered a simple questionnaire asking whether after three months of treatment they generally felt better, the same, or worse.
PRESENTATION OF RESULTS
The results are given separately for the population study, in which the initial measurements in the epileptic patients were compared with the values in the control groups 1 and 2, and for the effect of treatment where the epileptic patients' initial values were compared with their final values. As B.M.C. is a function of sex and age (table II), the B.M.C. values of the epileptics were compared with the mean value and standard deviation in the corresponding sex and age group of control subjects. In the evaluation of the results the following statistical tests were used (Bradford Hill, 1967) the normal range ( x 2 S.D.); these all belonged to groups A and C. The distributions, mean value, and standard deviation for serum alkaline phosphatase levels in the epileptic groups before trial and in reference group 2 are shown in table VI. The mean value of 5 6 units/100 ml (S.D. 1-4) in the 49 men in group 2 was significantly higher than the mean values of 4-7 units/ 100 ml (S.D. 1 4) in the 46 women (P <0 001). The statistical tests yielded P values of the same order, whether calculated from raw data or after logarithmic transformation. The mean value in the 226 epileptics was significantly higher than normal (P <0 001), and 97 of them (43",,) had serum alkaline phosphatase levels higher than the normal range (x +2 S.D., using corresponding normal values for men and women).
Relation (Jensen et al., 1972; Christiansen and Rddbro, 1973) . This is important for the good reproducibility of the method. The parameter used for B.M.C. (in arbitrary units) is related to the weight and calcium content of the bones in the forearm with very high coefficients of correlation (Christiansen and R&dbro, 1973) and is also well correlated to the weight of the total skeleton (r---0 90, Mazess, 1971 * Dose calculated in units according to Rici-iens and Rowe (1970) . N.S. = Not significant (P >0 05). The present findings indicate that all three groups of epileptics had similarly low B.M.C. values. On average the epileptics' total body calcium could be estimated at 87', of normal. About one-fifth had subnormal B.M.C. values. The degree of demineralization was related to the dose and duration of anticonvulsant therapy. Richens and Rowe (1970) found a correlation between the biochemical indices of osteomalacia and the dose of anticonvulsant.
As to the effect of the treatment, the results clearly showed that the B.M.C. rose in all epileptic groups in response to vitamin D, with an average increase of 4'y,. When the unchanged values in the control subjects (group 3) and the epileptics on placebo are considered the calculated positive calcium balance of 23 g over the three months could be ascribed to the daily therapeutic dose of 2,000 IU vitamin D2. These results confirm our previous preliminary communications , but disagree with the findings of Linde et al. (1972) . They were unable to find any effect on B.M.C. in nine patients who received 50,000 IU vitamin D daily for six months without supplementary calcium intake. This dose of vitamin D may have been too large.
Previous reports on epileptic inpatients have shown an incidence of hypocalcaemia of 23",, and 30'' Hunter et al., 1971) and 19",, for outpatients Hahn et al., 1972) . We found an incidence of 12",,. These disparities may be due to sampling from different populations and varying criteria for selection. Since the "non-response" sample in the present series was rather small our patients may be regarded as fairly representative of an epileptic outpatient population.
The incidence of raised serum alkaline phosphatase levels in epileptic inpatients on long-term anticonvulsant therapy has been reported to be 29()O and 240O Hunter et al., 1971) . In contrast to these reports we have found that 43 had increased values. The normal range calculated from our 95 group 2 control subjects was narrower than that given by Richens and Rowe (1970) in 82 subjects with a mean age of 34 years. This disparity is difficult to explain. However, by using the upper limit reported by Richens and Rowe (10 and 12 K.A. units/100 ml for women and men, respectively) the incidence of raised serum alkaline phosphatase in our series fell to 12%" (27 of the 226 patients).
The data given in table VII show that the biochemical and bone indices of osteomalacia are related. Furthermore, our results ;how that whereas these indices are suipplemletitary to diagnosi, of pathological conditions in anticonvulsant osteomalacia, the measurement of B.M.C. is the more sensitive index to evaluate treatment with vitamin D.
Osteomalacia is said to give various vague general symptoms. The answers to the questionnaire revealed that the patients felt no subjective improvement; this, however, is inconclusive, since the dose of vitamin D was rather small and given for only a limited period.
From the present controlled therapeutic trial in a large representative sample of epileptic outpatients it can be concluded that such patients have a lower than normal total body calcium, which over three months can be increased, but not to normal levels, by a relatively small daily vitamin D2 supplement. The question whether epileptics prophylactically should receive vitamin D is a cost-benefit problem which cannot be answered from the present study. 
